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The CYP19 gene (located on chromosome 15q21.1) codes for the
aromatase enzyme that controls the rate-limiting step in the
pathway of oestrogen synthesis from steroid precursors. It is
known that an increased risk of breast cancer in males is associated
with elevated serum oestrogen levels, for example in Klinefelter’s
syndrome (Jackson et al, 1965). The aromatase enzyme has been
observed within the stromal cells in a greater proportion of male
breast carcinomas than gynaecomastia cases, suggesting that
locally produced oestrogens may also have a significant role in the
development of male breast cancer (Sasano et al, 1996). It is there-
fore possible that variation in expression of the CYP19 gene could
affect the risk of developing male breast cancer.
A polymorphic tetranucleotide (TTTA) repeat sequence is
found in intron 5 of the CYP19 gene, 79 nucleotides downstream
from exon 4 (Means et al, 1989). This repeat sequence is relatively
close to the exon–intron border and may therefore be involved in
the determination of splicing sites (Kristensen et al, 1998). The
aim of this study was to determine whether the development of
male breast cancer is influenced by the length of this tetra-
nucleotide repeat sequence in the CYP19 gene.
METHODS
Case and control population selection
Male cases were taken from a consecutive series of 76 male breast
cancer patients treated in the South East of Scotland between 1974
and 1998. Samples were available for DNA extraction in 64 of
these cases. Control DNA samples were obtained from 79 healthy
males representative of the South East Scotland population.
Further details of male breast cancer cases and controls have
previously been described (Young et al, 1999). Ethical approval
for the study was obtained through the Lothian Regional Ethics
Committee.
Laboratory methods
DNA extraction was carried out from whole blood by standard
phenol–chloroform extraction. DNA extraction from wax-
embedded tissue was from 10-mm sections incubated at 55°C with
a lysis buffer and proteinase K.
Primers as previously described (Polymeropoulos et al, 1991)
were used for polymerase chain reaction (PCR): CYP19-F:
5¢-GCAGGTACTTAGTTAGCTAC-3¢; CYP19-R: 5¢-TTACAGT-
GAGCCAAGGTCGT-3¢. These generate PCR fragments that
include the polymorphic site. PCR reactions were performed in
50-ml aliquots, each containing 1 ´ buffer, 2 mM magnesium chlo-
ride (MgCl2), 200 mM deoxynucleoside triphosphates, 40 pmol of
each primer, 1 unit of Taq polymerase (Life Technologies™) and
approximately 100 ng DNA. The amplification was performed
using an OmniGene thermal cycler (Hybaid, UK) under the
following conditions: initial denaturation at 94°C for 3 min;
amplification for 38 cycles, with denaturation at 94°C for 45 s,
annealing at 53°C for 45 s and extension at 72°C for 45 s; final
extension at 72°C for 10 min.
The products were denatured and then run on 6% polyacryl-
amide gels with a 10 bp DNA ladder. The number of TTTA repeats
in homozygous products were measured by cycle sequencing and
these were used as size standards.
Data analysis
The distribution of alleles of the CYP19 gene, comparing male
breast cancer patients with controls, was analysed using the
Mann–Whitney test. Odds ratios with 95% confidence intervals
were calculated to show the risk of developing male breast cancer
associated with each allele.
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PCR was unsuccessful with ten of the DNA samples derived from
archival wax-embedded tissue sections, giving a total of 54 case
samples (108 alleles) analysed.
Seven different alleles of the CYP19 gene were detected
(Figure 1). The allele distribution of the CYP19 gene in male
breast cancer patients and controls is shown in Table 1. There were
no significant differences in the distribution of alleles between
cases and controls (P = 0.838). We have found two different alleles
containing seven TTTA repeats (corresponding to PCR products
of 168 bp and 171 bp in length). Cycle sequencing of these alleles
revealed that the shorter allele, designated (TTTA)7–3, had a 3-bp
(TTC) deletion 50 bp upstream from the 5¢ end of the TTTA repeat
sequence. One of the male breast cancer patients (MBC20) had an
allele containing 13 repeats. A blood sample was obtained from
his father (MBC20F), who had not had breast cancer. Analysis of
DNA extracted from this showed the same (TTTA)13 allele.
DISCUSSION
This is the first study that attempts to determine whether the devel-
opment of male breast cancer is influenced by the length of the
tetranucleotide repeat sequence within intron 5 of the CYP19 gene.
Two recent studies have determined the distribution of alleles
among female breast cancer patients and controls. The first of
these studies (Kristensen et al, 1998) found five different alleles
containing 7, 8, 9, 11 and 12 repeats. The allele containing 12
repeats was found significantly more frequently in female breast
cancer patients than in controls. The second of the studies
(Siegelmann-Danieli and Buetow, 1999) described eight different
alleles by PCR product length. Details of TTTA repeat number
were not given. Alleles of 168 bp and 171 bp in length were found,
presumably corresponding to the two different alleles containing
seven repeats found in our study, although the 3-bp deletion was
not characterized. This deletion has, however, been described
previously in a Japanese study (Kurosaki et al, 1997). From their
study, Siegelmann-Danieli and Buetow (1999) conclude that the
171 bp allele represents a high-risk allele, whereas the 187 bp and
191 bp alleles (corresponding to 11 and 12 repeats respectively,
from our data) are considered to confer low risk. These conclu-
sions are contradictory to those drawn by Kristensen et al (1998).
Contrary to published (and mutually incompatible) findings in
female breast cancer, our study found no significant differences in
distribution of alleles between male breast cancer cases and
controls. Patient MBC20, who has an allele with 13 repeats, was
diagnosed with breast cancer at a very young age (26 years), but
has no family history of cancer. This certainly represents a rare
variant within the South East Scotland population, but is most
likely to be an incidental finding.
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Figure 1 Examples of the seven different alleles of the CYP19 gene found
in male breast cancer patients and controls
Table 1 Distribution of alleles of the CYP19 gene in male breast cancer
patients and controls
Allele PCR product Cases Controls Odds ratio & 95%
length (bp) (n = 108) (n = 158) confidence interval
(TTTA)7–3 168 35 (32.4%) 48 (30.4%) 1.10 (0.649–1.86)
(TTTA)7 171 20 (18.5%) 30 (19.0%) 0.970 (0.518–1.82)
(TTTA)8 175 11 (10.2%) 16 (10.1%) 1.01 (0.448–2.26)
(TTTA)10 183 1 (0.93%) 2 (1.3%) 0.729 (0.0653–8.14)
(TTTA)11 187 36 (33.3%) 57 (36.1%) 0.886 (0.529–1.48)
(TTTA)12 191 4 (3.7%) 5 (3.2%) 1.18 (0.309–4.49)
(TTTA)13 195 1 (0.93%) 0 –
Heterozygosity 79.6% 79.7%